← Human Trials & Peer-Reviewed Studies
Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy.
Plain-language guide to PMID 28732565 (2017): clinical trial of Follistatin-344.
Key Facts
- PMID
- 28732565
- Journal
- Metabolism: clinical and experimental
- Year
- 2017
- Study type
- Clinical Trial
- Authors
- Anastasilakis AD et al. (9 authors)
- DOI
- 10.1016/j.metabol.2017.05.002
What This Study Did, in Plain Language
What Was Tested
Researchers studied Follistatin-344 in this clinical trial publication.
Several myokines are produced by cardiac muscle.
The researchers investigated changes in myokine levels at the time of acute myocardial infarction (MI) and following reperfusion in relation to controls.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
Patients with MI (MI Group, n=31) treated with percutaneous coronary intervention (PCI) were compared to patients with stable coronary artery disease (CAD) subjected to scheduled PCI (CAD Group, n=40) and controls with symptoms mimicking CAD without stenosis in angiography (Control Group, n=43).
How the Study Was Run
The number and degree of stenosis were recorded.
Irisin, follistatin, follistatin-like 3, activin A and B, ALT, AST, CK and CK-MB were measured at baseline and 6 or 24h after the intervention.
What Was Measured
The researchers investigated changes in myokine levels at the time of acute myocardial infarction (MI) and following reperfusion in relation to controls.
The subject headings attached to it are Activins, Case-Control Studies, Constriction, Pathologic, Coronary Angiography, Coronary Artery Disease, Creatine Kinase, MB Form and Diagnosis, Differential.
The authors tagged it with the keywords Follistatin, Irisin, Myocardial infarction and Percutaneous coronary intervention.
What This Means in Plain Language
This is a clinical trial of Follistatin-344.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2017 (Metabolism: clinical and experimental), a journal based in United States.
More context: the Follistatin-344 compound page, all human trials.
Our Notes on the Compound
Follistatin-344: A myostatin- and activin-binding protein studied in gene-therapy trials for muscular dystrophy; black-market vials have been found mislabeled.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.